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The lethal response to Cdk1 
inhibition depends on sister 
chromatid alignment errors 
generated by KIF4 and isoform  
1 of PRC1
Erik Voets1, Judith Marsman1, Jeroen Demmers2, Roderick Beijersbergen1 & Rob Wolthuis1,3
Cyclin-dependent kinase 1 (Cdk1) is absolutely essential for cell division. Complete ablation of Cdk1 
precludes the entry of G2 phase cells into mitosis, and is early embryonic lethal in mice. Dampening 
Cdk1 activation, by reducing gene expression or upon treatment with cell-permeable Cdk1 inhibitors, 
is also detrimental for proliferating cells, but has been associated with defects in mitotic progression, 
and the formation of aneuploid daughter cells. Here, we used a large-scale RNAi screen to identify 
the human genes that critically determine the cellular toxicity of Cdk1 inhibition. We show that 
Cdk1 inhibition leads to fatal sister chromatid alignment errors and mitotic arrest in the spindle 
checkpoint. These problems start early in mitosis and are alleviated by depletion of isoform 1 of 
PRC1 (PRC1-1), by gene ablation of its binding partner KIF4, or by abrogation of KIF4 motor activity. 
Our results show that, normally, Cdk1 activity must rise above the level required for mitotic entry. 
This prevents KIF4-dependent PRC1-1 translocation to astral microtubule tips and safeguards proper 
chromosome congression. We conclude that cell death in response to Cdk1 inhibitors directly relates 
to chromosome alignment defects generated by insufficient repression of PRC1-1 and KIF4 during 
prometaphase.
At the end of G2 phase, cells enter mitosis when the mitotic kinase cyclin B-Cdk1 is rapidly activated. 
Simultaneously, the Cdk1-counteracting phosphatase PP2A is inhibited downstream of cyclin B-Cdk1, 
enforcing phosphorylation of Cdk1 substrates. PP2A can be repressed by a kinase called Greatwall 
(Gwl)1–4, which is also a Cdk1 substrate5,6. In mitosis, the chromosomes are bi-oriented on the mitotic 
spindle. This leads to activation of APC/CCdc20, the ubiquitin ligase that targets cyclin B1 for proteas-
omal destruction7. Disappearance of cyclin B1 inactivates Cdk1. This is essential for mitotic exit and 
cytokinesis.
Previous work revealed that the majority of cyclin B-Cdk1 is activated before the G2-to-M transi-
tion8,9. Nevertheless, Cdk1 activation continues after nuclear envelope breakdown (NEB), until all the 
chromosomes are aligned in metaphase9,10. Cyclin B1 RNAi does not block mitotic entry but interferes 
with normal prometaphase9,11,12. Also cells that are unable to repress PP2A can enter mitosis even when 
phosphorylation of Cdk1 substrates remains incomplete1,2. Similar effects are reported of the highly 
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specific Cdk1 inhibitors purvalanol A and RO-3306: blockade of Cdk1 activity with high concentrations 
of RO-3306 arrests cells in G2 phase, similar to CDK1 gene ablation13–16. However, lower Cdk1 inhibitor 
concentrations still permit entry into mitosis but, subsequently, lead to errors during mitotic exit9,11,17. 
Here, we aimed to identify the molecular pathways that critically determine cellular survival after Cdk1 
inhibition, by performing a genome-wide resistance screen for the specific Cdk1 inhibitor RO-3306.
Results and Discussion
Optimal cyclin B-Cdk1 activity directs chromosome attachment to the mitotic spindle. We 
compared the cell cycle effects of different concentrations of the specific Cdk1 inhibitor RO-3306 and 
found that 16 hours of treatment with RO-3306 at 3–5 μ M increased the mitotic index significantly, while 
more completely blocking Cdk1 activity with 10 μ M RO-3306 arrested cells in G2 phase. Similar effects 
were seen in non-transformed retinal pigment epithelial (RPE1) cells and osteosarcoma (U2OS) cells 
(Fig.  1A). Interestingly, mitotic arrest after 3–5 μ M RO-3306 rapidly led to cell death, while G2 arrest 
after completely blocking Cdk1 activity was much less detrimental within this time window (Fig.  1B). 
Cleaved poly-ADP-ribose-polymerase (PARP) revealed the rapid induction of apoptosis after partial, but 
not after more complete, Cdk1 inhibition (Fig. 1C)18.
To investigate the fatal mitotic defects resulting from partial Cdk1 inhibition in more detail, we fol-
lowed dividing U2OS cells, endogenously tagged with EYFP at the cyclin B1 locus, by time-lapse fluo-
rescence microscopy (U2OS-CCNB1-EYFP)19. Low micromolar RO-3306 treatment caused only a short 
delay between nuclear translocation of cyclin B1 in prophase, and the onset of NEB (Fig. 1D; 12 min in 
3 μ M RO-3306 versus 4 min in untreated cells). Subsequently however, these cells arrested for approxi-
mately 100 minutes before initiating cytokinesis, while cyclin B1-EYFP remained stable (Fig. 1D,E). Cell 
division eventually started before the completion of anaphase (Fig.  1D). The majority of cells treated 
with Cdk1 inhibitor displayed multiple chromosomes closely to the spindle poles. These chromosomes 
stained positive for the spindle checkpoint marker Mad2 (Fig. 1F). The chromosomes were indeed not 
stably attached to spindle microtubules as revealed by the absence of kinetochore-localized astrin, a 
marker of plus-end microtubules bound to chromosomes (Fig. 1G)20–22. When co-treated with reversine, 
an Mps1 inhibitor that blocks signalling from unattached kinetochores23, the arrested cells rapidly exited 
mitosis without aligning their chromosomes, regardless of Cdk1 inhibition (Fig.  1H, Supplementary 
Fig. 1A; mitosis lasted 106 ± 3.46 min in 3 μ M RO-3306 or 11.3 ± 0.25 min in 3 μ M RO-3306 + 50 nM 
reversine). In the absence of reversine, this led to unequal segregation of sister chromatids and caused 
aneuploidy, often accompanied by the formation of micronuclei (Fig. 1I; 4 ± 1.16% micronucleated cells 
in untreated cells versus 61.3 ± 2.4% in 3 μ M RO-3306). Most of the RPE1 cells that left mitosis after 
prolonged Cdk1 inhibition eventually arrested in a 4n G1-like state. Partial depletion of Cdk1 or B-type 
cyclins by RNAi lead to identical defects in cell cycle progression and nuclear morphology as observed 
after prolonged RO-3306 treatment, providing important evidence that treatment with the inhibitor for 
several days specifically represses cyclin B-Cdk1 (Supplementary Fig. 2A–G)9,11,12,24. Taken together, these 
results show that optimal mitotic Cdk1 activity is particularly required to align the sister chromatids, 
inactivate the spindle checkpoint, and degrade cyclin B1. This may be surprising because cyclin B-Cdk1 
reportedly has a positive role in maintenance of the spindle checkpoint, too11,25. We investigated this 
paradox by measuring how long cells arrested when entering mitosis in the presence of nocodazole alone, 
which arrests cells in the spindle checkpoint, or in the combination of nocodazole with 3 μ M RO-3306. 
Partial inhibition of Cdk1 halved the duration of the nocodazole-induced delay. This showed that the 
spindle checkpoint is functional in cells entering mitosis with suboptimal Cdk1 activity, but maintenance 
of the checkpoint is weakened (Supplementary Fig. 1B,C; mitosis lasts 473 ± 12.6 min in nocodazole or 
240.8 ± 9.6 min in nocodazole + 3 μ M RO-3306). Collectively, these data demonstrate that incomplete 
activation of cyclin B-Cdk1 during mitosis perturbs chromosome alignment and subsequent satisfaction 
of the spindle checkpoint, and leads either to apoptosis, or, when cells eventually divide, to aneuploidy.
A role for PRC1 splice variant 1 in RO-3306 resistance, independent of cytokinesis. To find 
the genes most critically involved in RO-3306-induced lethality, we then carried out a large-scale RNAi 
screen with a collection of 23,742 short hairpin RNA (shRNA) vectors targeting 7,914 human genes26. 
Barcoding technology was used to identify genes whose knockdown supported survival and prolifer-
ation in the presence of 3 μ M RO-3306 (Fig.  2A). The results are shown in an M/A-plot, where each 
dot represents one individual shRNA vector (Supplementary Fig. 3A). M and A values reflect relative 
enrichment and hybridization signal intensities. We prioritized our candidates by applying the M/A 
cut-off values as indicated. Among the candidate hits, we identified short hairpins targeting a scaffold 
subunit of the PP2Aα complex, PPP2R1A, and protein regulator of cytokinesis 1 (PRC1), as mediators 
of RO-3306 resistance (Supplementary Fig. 3A). Each of the identified shRNAs were then retested for 
their ability to confer resistance to RO-3306, in comparison to a positive control, a shRNA targeting 
PPP2CA (the catalytic subunit of PP2Aα ). Of the shRNA vectors tested, the strongest bypass of RO-3306 
sensitivity was conferred by shPRC1 or shPPP2CA, and, partially, by shPPP2R1A (Supplementary Fig. 
3B,C). Conferred resistance by different knockdown vectors correlated with reduced expression of PRC1 
(Supplementary Fig. 3D,E). Expression of a shRNA-resistant PRC1 cDNA in PRC1-depleted U2OS cells 
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Figure 1. Partial inhibition of Cdk1 results in a spindle checkpoint-dependent mitotic arrest.  
(A) Flow cytometry of RPE1 and U2OS cells treated with increasing concentrations of RO-3306. Cells 
were treated for 16 hours (Mean ± s.e.m, n = 3). (B) Cell death correlates to entering mitosis, whereas a 
full blockade of Cdk1 activity prevents cell death. Cell death was determined by flow cytometry analysis. 
(Mean ± s.e.m, n = 3). (C) Partial Cdk1 inhibition triggers PARP cleavage. Lysates of U2OS cells are shown. 
(D) Cyclin B1 degradation in metaphase is delayed in cells with impaired Cdk1 activity. U2OS-CCNB1-
EYFP cells were followed by differential interference contrast (DIC) and fluorescence microscopy. NEB, 
nuclear envelope breakdown; nt, nuclear translocation; ana, anaphase. Scale bar, 10 μ m. (E) Quantification of 
the cyclin B1-EYFP levels in cells treated with or without 3 μ M RO-3306. Fluorescence intensity was plotted 
against time after NEB. (Mean ± s.e.m, n = 3, untreated = 20 cells analysed, 3 μ M RO-3306 treated = 13 
cells analysed). (F) Unaligned sister chromatids are detected by the mitotic checkpoint. U2OS cells, treated 
with or without 3 μ M RO-3306 were fixed after 16 hours. Mad2-positive kinetochores are indicative of a 
functional spindle checkpoint. Insets: overlay of Mad2 and CREST stainings. Scale bar, 10 μ m. (G) Partial 
Cdk1 inhibition results in sister chromatid attachment defects to the mitotic spindle. Treatments are 
performed as in (F). Sister chromatid pairs that are not aligned are negative for kinetochore-associated 
astrin. Insets: overlay of astrin and CREST stainings. Scale bar, 10 μ m. (H) Quantification of the mitotic 
duration after partial Cdk1 inhibition in presence or absence of a functional checkpoint. Mitosis is plotted 
from NEB till anaphase. (Mean ± s.e.m, n = 3, 50 cells/experiment; ****p < 0.0001, Student’s t test). (I) Cdk1 
inhibition results in the formation of micronuclei during mitotic exit. Analysis is performed using the cells 
from panel (H). (Mean ± s.e.m, n = 3, 50 cells/experiment; ***p < 0.001, Student’s t test). Western blots in 
panel (C) have been cropped and full-length gels can be viewed in Supplementary Fig. 6.
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Figure 2. A shRNA barcode screen identifies PRC1 as critical mediator of the anti-proliferative effects 
of RO-3306. (A) Schematic outline of the RO-3306 barcode screen in U2OS cells. (B) Reconstitution of the 
RNAi-resistant human PRC1-1 cDNA in PRC1 knockdown cells. The pRS vector (shCTRL) was used as a 
control. (C) Western blot analysis of protein lysates corresponding to the cell lines shown in (B). shPRC1 
Lib#1 targets only endogenous PRC1, while shPRC1 Lib#2 is able to target both endogenous and Venus-
NT-PRC1 #1. (D) Western blot analysis of U2OS cells stably expressing individual Venus-PRC1 isoforms 
after transfection of siRNA duplexes specifically targeting the indicated splice variants. CTRL refers to 
cells lacking ectopic expression of Venus-PRC1. (E) Depletion of PRC1-1 rescues cell proliferation when 
Cdk1 activity is compromised. The functional phenotypes of the individual shRNAs targeting the PRC1 
variants are indicated by the colony formation assay. The pRS vector (shCTRL) was used as a control. 
The knockdown efficiency of each individual shRNA was measured by examining the mRNA level of the 
PRC1-1 and PRC1-2 target genes by qRT-PCR. (Mean ± s.d. n = 3). (F) KIF4 is a PRC1 binding partner. 
Immunoprecipitations (IPs) with GFP-Trap_A beads were performed on extracts of U2OS WT (CTRL) or 
U2OS cells stably expressing Venus-PRC1-1 (PRC1-1). Aliquots of the IPs were analysed by SDS-PAGE. 
(G) Compromised Cdk1 activity in mitosis results in premature binding of PRC1 to KIF4. U2OS cells 
were synchronised in mitosis using thymidine and nocodazole. Cells arrested in mitosis were obtained 
by mitotic shake-off, released from the nocodazole and harvested after 60 minutes (G1) or, alternatively, 
treated with 5 μ M MG132 with or without 3 μ M RO-3306 and harvested after 30 minutes (M). Cell extracts 
were subjected to immunoprecipitation using a rabbit anti-PRC1. Aliquots of the immunoprecipitates were 
analysed by Western blotting. The signal intensity of the KIF4 band in the PRC1 IP was quantified and 
normalized to 1 for the G1 sample. *p < 0.05, Student’s t test. Western blots in panels (C,D,F,G) have been 
cropped and full-length gels can be viewed in Supplementary Fig. 6.
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restored the sensitivity of these cells to Cdk1 inhibition, further supporting the specificity of the PRC1 
shRNAs (Fig. 2B,C).
PRC1 is a well-conserved microtubule-associated protein. In mammalian cells, it plays a vital role 
in the establishment of the spindle midzone, required for cytokinesis27. Mammalian cells express three 
different PRC1 splice variants. These variants have different carboxyl termini. PRC1-2 is activated by 
Plk1 phosphorylation and controls cytokinesis28. To further address the contribution of the PRC1 splice 
variants to RO-3306 sensitivity, siRNA duplexes were designed which specifically depleted each of the 
different PRC1 isoforms (Fig. 2D). Depletion of either PRC1-1 or PRC1-3 allowed cells to bypass Cdk1 
inhibition. PRC1-1 depletion conferred the strongest resistance to higher doses of RO-3306 (Fig.  2E). 
Importantly, on its turn, only PRC1-2 cDNA expression restored the cytokinesis defects that were caused 
by depletion of all PRC1 isoforms (Supplementary Fig. 4A,B). Furthermore, overexpression of PRC1-2 did 
not sensitize U2OS cells to Cdk1 inhibition, while overexpression of PRC1-1 clearly did (Supplementary 
Fig. 4C,D). These results identify PRC1, and particularly the isoform PRC1-1, as a factor that critically 
determines the cellular sensitivity to Cdk1 inhibition.
Removal of the PRC1 interactor KIF4 restores mitosis after Cdk1 inhibition. To gain fur-
ther insight into the role of PRC1-1, we conducted a tandem mass spectrometry experiment to find 
its interacting proteins. We identified many of the known PRC1 binding partners, but particularly the 
chromokinesin KIF429 (Supplementary Fig. 5A). Western blotting of anti-GFP immunoprecipitations 
confirmed the interaction between Venus-PRC1-1 and endogenous KIF4 (Fig. 2F). Partial inhibition of 
Cdk1 in mitotic cells resulted in KIF4-PRC1 protein complex formation and was further increased after 
mitosis, when Cdk1 is inactive (Fig. 2G, left panel; right panel shows expression levels).
We then tested the effect of KIF4 knockdown by multiple independent shRNAs, which all rendered 
cells resistant to RO-3306, similar to the knockdown of PRC1 (Supplementary Fig. 5B,C). Furthermore, 
reconstitution of KIF4 knockdown U2OS cells by the RNAi-resistant human WT KIF4 cDNA fully 
restored the sensitivity of these cells to Cdk1 inhibition (Fig.  3A,B). Active KIF4 inhibits microtubule 
plus-end dynamics to minimize the length of overlapping PRC1-bound microtubules within the spindle 
midzone30–32. To test whether the RO-3306–induced lethality also depended on the motor activity of 
KIF4, we expressed two different KIF4 mutants to complement KIF4 knockdown cells: a phosphorylation 
mutant that is expected to be less active in mitosis (KIF4A/A)33, and an ATPase inactive or motor-dead 
mutant (KIF4md)34. This experiment showed that the growth inhibitory effects of RO-3306 strongly 
depended on the ATPase activity of KIF4 (Fig. 3A,B). The A/A mutant was limited in its ability to restore 
RO-3306 sensitivity, in line with its moderately impaired motor activity33. Reciprocally, overexpression 
of GFP-tagged human or mouse KIF4 cDNA was sufficient to increase the toxicity of RO-3306 in U2OS 
cells (Supplementary Fig. 5D,E). So, reducing the expression of KIF4 renders Cdk1 inhibition less toxic, 
while increasing the abundance of KIF4 aggravates toxicity. To prove the specificity of the KIF4 pheno-
type, we disrupted the KIF4 gene in U2OS cells using CRISPR/Cas-mediated gene targeting. Successful 
gene ablation resulted in the disruption of exon 2 of the KIF4 gene by a blasticidin resistance (BlastR) 
gene (Supplementary Fig. 5F). In addition, immunostaining revealed the complete loss of the KIF4 pro-
tein (Supplementary Fig. 5G). Despite some clonal differences, gene ablation of KIF4 again rescued 
cellular proliferation in the presence of low doses of RO-3306 (Fig.  3C,D). Further characterization of 
one of these KIF4 knockout clones (KIF4 KO clone 16) demonstrated that loss of KIF4 rescued chromo-
some alignment under conditions when Cdk1 was partially inhibited (Fig. 3E, Supplementary Fig. 5H).
To study the spindle, and chromosome alignment, in further detail, we depleted KIF4 from a sta-
ble cell line co-expressing the markers H2B-GFP and mCherry-α -Tubulin. KIF4 depletion resulted in 
an elongated spindle midzone when compared to control cells, an effect published before35 (Fig.  3F). 
Western blotting confirmed that KIF4 was not expressed (Fig. 3G). Importantly, KIF4 RNAi shortened 
the duration of prometaphase in RO-3306 (Fig. 3H; siCTRL, 123.7 ± 4.65 min; siKIF4, 81.7 ± 2.16 min). 
At the same time, KIF4 depletion reduced the formation of micronucleated cells significantly (Fig.  3I; 
siCTRL, 66.7 ± 1.76%; siKIF4, 24.7 ± 1.76%). Under untreated conditions, we did not observe any change 
in the duration of NEB until anaphase, or the amount of micronucleated daughter cell formation when 
KIF4 was suppressed. These data indicate that PRC1 and KIF4 act in a similar fashion and critically 
mediate the inhibitory effects of RO-3306 on mitosis. We conclude that, like the suppression of PRC1-
1, removal of KIF4 restores chromosome alignment, cell viability and genomic integrity when Cdk1 is 
inhibited.
KIF4 directs chromosome alignment by regulating the stability of the mitotic spindle. Next, 
we investigated whether depletion of KIF4 or PRC1 affected the dynamics of spindle formation and 
chromosome alignment in RO-3306. We conducted a nocodazole washout assay that reveals how effi-
ciently kinetochores can establish stable microtubule attachments as the spindle forms (Fig.  4A). At 
time points up to 60 min after nocodazole washout, we measured the fraction of cells with fully aligned 
chromosomes at the metaphase plate. Examples of misaligned and fully aligned chromosomes are shown 
in Fig.  4B. The dynamics of alignment were unchanged in the absence of RO-3306 when either KIF4 
or PRC1 was suppressed (Fig.  4C, left panel). In control cells, partial inhibition of Cdk1 completely 
abolished alignment of the chromosomes up to 40 min after nocodazole washout, but depletion of 
either KIF4 or PRC1 clearly restored alignment under these conditions (Fig. 4C, right panel). Western 
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Figure 3. Suppression of the PRC1 interactor KIF4 improves the mitotic cell fate when Cdk1 activity 
is compromised. (A) The ATPase activity of KIF4 is required for the RO-3306–induced cellular toxicity. 
Reconstitution of KIF4 knockdown U2OS cells with either WT, a phosphorylation-mutant, or an ATPase-
dead KIF4 cDNA (KIF4WT, KIF4A/A, or KIF4md, respectively). (B) Western blot analysis of protein lysates 
corresponding to the cell lines shown in (A). shKIF4 3′UTR targets endogenous KIF4. (C) KIF4 knockout 
cells are resistant to Cdk1 inhibition. U2OS WT or KIF4 knockout cell clones treated with increasing 
concentrations of RO-3306 were examined by colony formation assay. KO, knockout. (D) U2OS WT 
and KIF4 KO clones were characterized by Western blot analysis. Cell lysates correspond to the colony 
formation assay in (C). (E) KIF4 KO cells restore chromosome alignment in mitosis when Cdk1 activity is 
compromised. U2OS WT, KIF4 KO clone 16, and KIF4 KO clone 16 reconstituted with GFP-KIF4WT were 
treated with or without 3 μ M RO-3306 for 16 hours and MG132 for two hours to allow cells to arrest in 
metaphase. Subsequently, cells were fixed and the alignment status was determined by immunofluorescence. 
(Mean ± s.e.m, n = 3, at least 50 cells/experiment; n.s., not significant; **p < 0.005, Student’s t test). (F) U2OS 
cells stably expressing H2B-GFP and mCherry-α -Tubulin were imaged by DIC and fluorescence microscopy, 
48 hours after transfection with indicated siRNAs. Scale bar, 10 μ m. (G) Verification of the KIF4 depletion 
judged by Western blot analysis. (H) KIF4 depletion rescues the mitotic delay upon compromised Cdk1 
activity. Cells shown in (F) were followed 48 hours after transfection with indicated siRNAs. Mitosis is 
plotted from NEB until anaphase. (Mean ± s.e.m, n = 3, 50 cells/experiment; ****p < 0.0001, Student’s t test). 
(I) KIF4 knockdown rescues abnormal mitotic exit and chromosome loss when Cdk1 is partially active. 
Analysis is performed with cells shown in (H). (Mean ± s.e.m, n = 3, 50 cells/experiment; ****p < 0.0001, 
Student’s t test). Western blots in panels (B,D,G) have been cropped and full-length gels can be viewed in 
Supplementary Fig. 6.
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Figure 4. KIF4 and PRC1 repress chromosome congression when Cdk1 is partially active. (A) Experimental 
setup of a nocodazole washout assay. Thymidine blocked cells are released, nocodazole-arrested, and washed 
free from nocodazole to allow spindle assembly in presence of the proteasome inhibitor MG132, together with 
RO-3306. (B) Representative immunofluorescence images of mitotic cells, before and after nocodazole washout. 
Examples of different alignment defects are shown. Scale bar, 10 μ m. (C) PRC1 and KIF4 prevent chromosome 
alignment when Cdk1 activity is compromised. Bar graph shows a quantification of the experimental setup 
shown in (A). (Mean ± s.e.m, n = 3, at least 150 cells/experiment). (D) Western blot analysis of the experiment in 
(C) shows the knockdown efficiency of the shRNAs targeting KIF4 or PRC1. (E) PRC1 present at microtubule 
overlaps partly localizes to astral microtubules after suppression of Cdk1 activity. U2OS cells were treated with 
or without 3 μ M RO-3306 for 16 hours, fixed, and processed for immunofluorescence. Insets demonstrate 
PRC1 localization to astral microtubules in the vicinity of unaligned chromosomes when Cdk1 is inhibited. 
Scale bar, 10 μ m. (F) PRC1 localization to astral microtubules is dependent on the presence of KIF4. U2OS 
WT or KIF4 KO cells were treated and processed as in (E). Prometaphase cells were scored for the presence 
of PRC1 on astral microtubules (MTs). Scale bar, 10 μ m. (Mean ± s.e.m, n = 3, at least 30 cells/experiment; 
****p < 0.0001, Student’s t test). (G) Schematic overview of the progression from prometaphase to metaphase 
with normal or compromised cyclin B-Cdk1 activity. Maximal Cdk1 activation directs chromosome alignment 
and the establishment of stable k-MT attachments in metaphase. Partial reduction in Cdk1 activity by RO-3306 
treatment results in a prometaphase arrest that is dependent on KIF4 and PRC1. Due to a weakened spindle 
checkpoint, cells will exit from mitosis with lagging chromosomes leading to the formation of micronuclei. 
Western blots in panel (D) have been cropped and full-length gels can be viewed in Supplementary Fig. 6.
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blot analysis confirmed the knockdown of both KIF4 and PRC1 (Fig. 4D). When cells entered mitosis 
under conditions of partial Cdk1 inhibition, PRC1 remained incompletely phosphorylated on Thr481 
during prometaphase and was recruited to misaligned chromosomes as well as what appear to be astral 
microtubule tips: microtubules moving away from the mitotic spindle towards the cell cortex (Fig. 4E,F, 
Supplementary Fig. 4E,F). The effect of RO-3306 on PRC1 was completely dependent on KIF4 (Fig. 4F). 
We conclude that, normally, PRC1 and KIF4 are kept inactive in early mitosis by Cdk1, which is essen-
tial for the prometaphase-to-metaphase transition and for successful mitosis33,36. Entering mitosis in 
the presence of Cdk1 inhibitors renders KIF4 abnormally active, directing the translocation of PRC1-1 
to astral microtubule tips. This interferes with the formation of stable k-MT attachments, leading to 
chromosome alignment defects and a spindle checkpoint-dependent arrest, and results in cell death or 
aneuploidy (Fig. 4G).
Conclusions
Our results reveal that Cdk1 inhibition triggers cell death, in line with previous reports12,14,16,37–39. 
Importantly, we demonstrate that short-term treatment with a low dose of RO-3306 induces mitotic 
arrest and cell death, or aneuploidy, and this occurs independently of endoreduplication cycles. Mitotic 
failure may lead to nuclear fragmentation, thereby generating daughter cells with characteristic micronu-
clei. These micronuclei are a well-known hallmark of chromosomal instability (CIN) and aneuploidy40,41. 
Micronucleated cells are often eliminated by caspase-3-mediated apoptosis42. PRC1-1 or KIF4 deple-
tion reduces the amount of micronucleated cells, which may explain the increased cell viability upon 
RO-3306 treatment. Additionally, PRC1-1 and KIF4 RNAi facilitate sister chromatid alignment and 
passage through the spindle checkpoint, vitally shortening the duration of mitosis in the presence of 
RO-3306 and preventing the accumulation of death signals in mitosis43.
Thus far, it was unclear which Cdk1-regulated factors direct the timing of k-MT attachment stabiliza-
tion. Our results reveal that PRC1 and KIF4 each fit this role. PRC1 is a Cdk1 substrate that is repressed 
by phosphorylation of both Thr470 and Thr481 during prometaphase, preventing its oligomerization and 
microtubule bundling activity27,36,44. The inability to phosphorylate PRC1 causes defects in chromosome 
alignment and an arrest in mitosis36. Remarkably, our results support a cytokinesis-independent role 
of PRC1 in cell survival after Cdk1 inhibition: we find that PRC1-1 is the key PRC1 splice variant that 
contributes to RO-3306 sensitivity from prometaphase onwards. The localization of PRC1-1 drastically 
changes upon partial inhibition of Cdk1, from microtubules at overlapping spindle halves, to both polar 
and astral microtubules.
KIF4 has a binding preference for dephosphorylated PRC1, so the interaction between KIF4 and 
PRC1 normally occurs after cyclin B destruction and PP2A-B55 activation34,45. Thus far, we have no 
evidence for direct control of KIF4 by Cdk1. We hypothesize that, under conditions of Cdk1 inhibition, 
KIF4 reduces the growth of anti-parallel microtubule overlaps, formed by PRC1 in prometaphase. This 
suppresses the dynamic growth of microtubule plus-ends, leading to an inability to capture chromosomes 
and congress them to the metaphase plate.
In initial clinical trials, maximal inhibition of Cdk1 did not appear to be very successful in the treat-
ment of human cancers. However, Cdk1 inhibition is relatively efficient in the treatment of Myc-driven 
tumors46. Possibly, Cdk1 inhibition works better as an anti-cancer strategy when the targeted cells do 
not arrest in G2 phase, but undergo a fatal mitosis. The expression levels of PRC1-1 and KIF4 in tum-
ors could be factors influencing the outcome of treatment with Cdk1 inhibitors. These ideas will be the 
subject of further studies.
Methods
Cell culture and synchronization. Cells lines were cultured in DMEM (Gibco) containing 8% 
heat-inactivated FBS (Hyclone) supplemented with 100 U/ml penicillin and 100 μ g/ml streptomycin at 
37 °C in 5% CO2. 24 or 48 hours before synchronization, transfection or treatment, cells were seeded 
on either 6-well Costar plates or 9 cm Falcon dishes. For time-lapse fluorescence microscopy, cells were 
seeded onto 3.5 mm glass-bottom dishes (Wilco Wells) or 4- to 8-well glass-bottom dishes (Labtek II). 
For enrichment of cells in mitosis, cells were treated for 24 hours with thymidine (2.5 mM final concen-
tration [Sigma-Aldrich]), released into fresh medium and subsequently treated with nocodazole (415 nM 
final concentration [Sigma-Aldrich]) for 16 hours. For alignment assays, cells were released from the noc-
odazole block and cultured in medium containing MG132 (#13697, 5 μ M final concentration [Cayman 
Chemicals]) to block the cells in metaphase.
Other drugs in this study are used as indicated: RO-3306 (#217699 [Calbiochem]); Mps1 inhibitor 
reversine (#10004412, 50 nM final concentration [Cayman Chemicals]).
shRNA library screen. U2OS cells were infected with retroviruses representing the complete 
Netherlands Cancer Institute (NKI) shRNA library described previously26. In brief, infected cells were 
selected on puromycin (2.0 μ g/ml) for three days and split into two populations. One population was 
left untreated and harvested after 7 days, while the other population was continuously exposed to the 
Cdk1 inhibitor RO-3306 and harvested after 22 days. The barcode screen was performed as described 
previously26,47.
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Plasmids and siRNA. Homo sapiens cDNAs for KIF4 and the different PRC1 splice variants were 
PCR amplified from pcDNA5/FRT/TO/EGFP-KIF4 and pCRII.topo-PRC1, respectively and cloned 
into pEGFP-C1 or pVenus-C1 (Takara Bio Inc.) using BglII-HindIII or EcoRI-SalI sites. The viral plas-
mids pLIB-GFP-KIF4 and pLIB-Venus-PRC1-1/-2/-3 were constructed by subcloning the inserts into 
a modified pLIB vector. Mutants of PRC1 and KIF4 were made by site-directed mutagenesis using the 
Venus-PRC1 isoforms or GFP-KIF4 as a template. The GFP-tagged versions of KIF4A/A and KIF4md were 
generated as described33,34. A Mus musculus variant of KIF4 was subcloned from pEGFP-mKIF4 to gen-
erate pLIB-GFP-mKIF4.
For the generation of pRetroSuper-Puro vectors targeting human KIF4, PPP2CA, PPP2R1A, and 
PRC1, the 19- or 21-nucleotide sequences were used as described in Supplementary Table 1. The PRC1 
isoforms were targeted with 19-nucleotide sequences designed to match the unique splice junctions as 
described previously28. The shPRC1 pool refers to a combination of 4 individual shRNAs (e.g. shPRC1#2, 
#5, Lib#1, and Lib#2) targeting PRC1.
The siRNAs to target KIF4 or PRC1 were purchased from Thermo Fisher Scientific as set of four 
individual ON-TARGET-plus oligos (see Supplementary Table 2).
Transfections and infections. U2OS cells stably expressing H2B-GFP and mCherry-α -Tubulin 
were generated by retroviral infection with pRS-H2B-GFP and pCX-mCherry-α -Tubulin, respectively. 
Cell lines expressing GFP-KIF4 or the different Venus-PRC1 splice variants were generated by retroviral 
infection with either modified versions of pLIB-GFP-KIF4 or the pLIB-Venus-PRC1 splice variants.
A CRISPR sgRNA was designed (using the CRISPR tool available at http://crispr.mit.edu/) target-
ing the human KIF4 gene (exon 2; 5′ -ATTTGATCCCTCTACTGAAC-3′ ) and cloned into the BbsI 
site of PX330 (http://www.addgene.org/42230/)48. U2OS cells were transfected with the gene-specific 
PX330 vector in addition to an excision vector containing a sgRNA to the zebrafish TIA gene 
(5′ -GGTATGTCGGGAACCTCTCC-3′ ) and a cassette of a 2A sequence followed by a blasticidin resist-
ance gene, flanked by two TIA target sites. Co-transfection with PX330 results in excision of the cassette 
from the plasmid and subsequent sporadic incorporation at the site of the targeted genomic locus by 
non-homologous end joining49. Transfections were carried out using X-tremeGENE 9 (Roche) according 
to the manufacturer’s instructions. Successful integration of the cassette into the targeted gene disrupts 
the allele and renders cells resistant to blasticidin. Four days following transfection the culture medium 
was supplemented with blasticidin (10 mg/ml). Surviving colonies were clonally expanded and screened 
for cassette integration into the query gene by PCR.
For siRNA transfections, cells were seeded into 6-well plates and transfected twice (with a 24 hour 
time-interval) using 40 nM siRNA. Transfection of siRNA pools were performed using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions. For time-lapse microscopy, cells were 
seeded into Labtek II 4- to 8-well glass-bottom dishes after the second siRNA transfection, or alterna-
tively, harvested for Western blot analysis.
Antibodies. Antibodies against the following proteins were used: goat anti-actin (Santa Cruz 
sc-1616), mouse anti-α -Tubulin (Sigma T5168), ANA-Centromere CREST AutoAb Human (Fitzgerald 
90C-CS1058), mouse anti-APC3 (BD Transduction #610455), rabbit anti-astrin (Bethyl Laboratories 
A301-512A), mouse anti-Cdk1 (BD Transduction 610038), rabbit anti-Cdk2 (Santa Cruz sc-163), rabbit 
anti-CENP-E (Sigma C7488), rabbit anti-cleaved PARP (Cell Signaling #5625S), mouse anti-cyclin B1 
(Santa Cruz sc-245), rabbit anti-cyclin B2 (Santa Cruz sc-22776), rabbit anti-KIF4 (Bethyl Laboratories 
A301-074A), rabbit anti-Mad2 (Bethyl Laboratories A300-301A), goat anti-phospho-PRC1 Thr481 (Santa 
Cruz sc-11768), mouse anti-PRC1 (BioLegend 629002), rabbit anti-PRC1 (Santa Cruz sc-8356). Secondary 
peroxidase-conjugated antibodies were obtained from DAKO and ALEXA fluorescently-labelled second-
ary antibodies were purchased from Molecular Probes.
Flow cytometry. For analysis of the cell cycle distribution, the entire cell population was analyzed 
by harvesting the medium containing the fraction of floating cells (e.g. dead and mitotic cells) together 
with the adherent cells (using 0.05% Trypsin-EDTA to detach the cells). Subsequently, cells were washed 
two times with PBS containing 0.01% Tween-20. Finally, the cells were fixed in 70% ice-cold ethanol 
and stained with rabbit anti-phospho-Histone H3 Ser10 (#06-570, 1:400 [EMD Millipore]). Cells were 
counterstained with propidium iodide (Sigma) diluted in RNase-containing PBS. Phospho-Histone H3 
positivity of the cells was analysed using FCS Express 2 (De Novo Software).
Western blotting and immunoprecipitations. Cells were lysed in ELB + (150 mM NaCl, 50 mM 
HEPES (pH 7.5), 5 mM EDTA, 0.3% NP-40, 10 mM β -glycerophosphate, 6% glycerol, 5 mM NaF, 1 mM 
Na3VO4 and Roche protease inhibitor cocktail). Lysates were cleared by centrifugation (13,000 × g, 
10 min at 4 °C). Protein levels were equalized by Bradford assay. For immunoprecipitations, 2 μ g anti-
bodies were precoupled for 4–12 hours to 20 μ l of protein G Sepharose (Amersham Biosciences) and 
washed with ELB + . Precoupled beads and lysates were incubated for 4 hours at 4 °C and washed three 
times with 1.0 mL of ice-cold ELB + . All remaining buffer was then removed and beads were resus-
pended in 50 μ L Laemmli sample buffer; 25 μ L was separated on SDS-PAGE and blotted on nitrocellulose 
(0.4 μ m pore). Immunoprecipitations of GFP for mass spectrometry were performed with GFP-Trap_A 
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beads (Chromotek), according to the manufacturer’s protocol. Membranes were blocked with 5% ELK in 
PBS containing 0.1% Tween. Development of blots was performed using the Chemidoc Imaging System 
(Bio-Rad Laboratories) and quantification was done with the Image Lab (Bio-Rad Laboratories) software.
Immunofluorescence. Cells were grown on glass coverslips and fixed with 3.7% formaldehyde in 
PBS (containing Ca2+ and Mg2+) for 10 min followed by permeabilization for 10 min with 0.1% Triton 
X-100 in PBS (Ca2+ and Mg2+). Cells were blocked in PBS (Ca2+ and Mg2+) containing 10% FBS and 
labelled with primary antibodies as indicated. Cells were washed 3 times followed by labelling with Alexa 
Fluor secondary antibodies. Staining of F-actin was carried out using Phalloidin-568 (Molecular Probes). 
DNA staining was performed with 4′,6-Diamidino-2-phenylindole (DAPI [Molecular Probes]) after 
which the coverslips were mounted in Vectashield solution. For endogenous KIF4 and PRC1 stainings, 
cells were pre-permeabilized for 3–5 min in PHEM buffer (100 mM PIPES pH 6.8, 25 mM HEPES pH 7.4, 
5 mM EGTA, 2.5 mM MgCl2) plus 0.5% Triton X-100. Then, cells were fixed for 10 min in PHEM buffer 
containing 3.7% formaldehyde. Mitotic PRC1 phosphorylation was monitored after ice-cold methanol 
fixation. Calcium-stable microtubule stainings were carried out as described previously50. Subsequent 
steps were performed as described above. z-stacks with 0.2 μ m spacing were acquired using a DeltaVision 
Elite system (Applied Precision). Maximum intensity projection of the z-levels were analysed with ImageJ 
(National Institute of Health) and processed using Photoshop and Illustrator software (Adobe).
Time-lapse fluorescence microscopy. U2OS cells were transfected with indicated siRNAs and 
followed by fluorescence time-lapse microscopy. Acquisition of DIC and fluorescence images started 
24 or 48 hours after transfection on an automated microscope (Axio Observer Z1; Carl Zeiss) in a 
heated culture chamber (5% CO2 at 37 °C) using DMEM with 8% FCS and antibiotics. The micro-
scope was equipped with an LD 0.55 condenser and 40x NA 1.40 Plan Apochromat oil DIC objective 
and CFP/YFP and GFP/HcRed filter blocks (Carl Zeiss) to select specific fluorescence. Images were 
taken using AxioVision Rel. 4.8.1 software (Carl Zeiss) with a charge-coupled device camera (ORCA 
R2 Black and White CCD [Hamamatsu Photonics] or Roper HQ [Roper Scientific]) at 100-ms expo-
sure times. Alternatively, imaging was performed on a Deltavision Elite system, using Leibovitz’s L-15 
(Gibco) CO2-independent medium, in a 37 °C culture chamber. For quantitative analysis of degradation, 
MetaMorph software (Universal Imaging), ImageJ and Excel (Microsoft) were used. Captured images 
were processed using Photoshop and Illustrator software.
RNA isolation and qRT-PCR analysis. Total RNA was extracted from U2OS cells grown on 6-well 
plates using the Quick-RNA MiniPrep kit (Zymo research) and quantified using NanoDrop (Thermo Fisher 
Scientific). cDNA was synthesized using SuperScript II reverse transcription, random hexamer primers 
(Promega), and 1 μ g of total RNA according to the manufacturer’s protocol. Primers were designed with 
a melting temperature close to 60 °C to generate 90–120 bp amplicons, mostly spanning introns. cDNA 
was amplified for 40 cycles on a 7500 Fast Real-Time PCR System (Applied Biosystems) using PCR 
mix reaction (FastStart Universal SYBR green mastermix [Roche]). Target cDNA levels were analysed 
by the comparative cycle (Ct) method and values were normalized against glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) expression levels. Information regarding the nucleotide sequences used for 
qRT-PCR analysis can be found in Supplementary Table 3.
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